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Abstract
In the healthy hepatocyte, uptake of bile acids across the basolateral membrane and export via the canalicular export pump,
are tightly coupled. Impairment of bile formation or excretion results in cholestasis, characterized by accumulation of bile
acids in systemic blood and within the hepatocyte. When the concentration of bile acids exceeds the binding capacity of the
binding protein located in the cytosol of the hepatocyte, bile acids induce apoptosis and necrosis, by damage to mitochondria.
Mitochondria play a central role on the toxicity of bile acids. In this article, we review the published literature regarding bile acid
effects on cell function, especially at the mitochondrial level. In patients with cholestatic liver disease, the extent of hepatocyte
damage caused by intracellular accumulation of bile acids appears to be delayed by ingesting a hydrophilic bile acid. However,
its effects on disease progression are not completely clarified. Therefore, identification of the mechanisms of cell injury will
be of clinical utility, helping in the development of new therapeutic strategies. The goal of this review is to include a fresh
consideration of all possible targets and integrating pathways that are involved in cholestasis, as well as in the benefits of bile
acid therapy.
© 2004 Elsevier Ireland Ltd. All rights reserved.
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1. Bile acids in health and disease
Bile acids are the major organic solutes in bile,
and under physiological conditions, they are chiefly
confined to the enterohepatic circulation. However, in
cholestasis (a pathophysiologic condition of the liver
defined as an impairment of bile formation) (Javitt,
1982), the enterohepatic circulation is interrupted and
bile acids accumulate within the liver.
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1.1. Clinical significance of bile acid synthesis
Bile acids, and their salts are natural products, fun-
damental constituents of bile. The determining phys-
iological action of bile acids is the emulsification of
bile lipids, in particular cholesterol. In view of this,
bile acid synthesis and subsequent excretion in the
feces represent the only significant mechanism for
the elimination of excess cholesterol. Their emulsify-
ing action also facilitate the intestinal absorption of
fat-soluble vitamins and the digestion of dietary tri-
acylglycerols, rendering fats accessible to pancreatic
lipases. Moreover, bile is an important route of elim-
ination of environmental toxins, carcinogens, drugs
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and their metabolites. Besides cholesterol, other en-
dogenous compounds and metabolic products, such as
bilirubin and hormones, are also excreted in the bile
(Nathanson and Boyer, 1991).
1.2. Bile acid synthesis
The synthesis of C24 bile acids (which are present
in most vertebrates) from cholesterol, in the liver, re-
quires the coordinated actions of a dozen enzymes lo-
cated in every major compartment of the hepatocyte
(Russell and Setchell, 1992). In this pathway, the ad-
dition of hydroxyl groups and the oxidation of the side
chain, form a soluble end product from cholesterol.
Although the pattern of hydroxylation varies between
species, the hydroxylation is always on one side of
the molecule, having the final product invariably a hy-
drophobic face and a hydrophilic face, resulting in an
amphipathic molecule (Fig. 1). However, the differ-
Fig. 1. Structures of major bile acids.
ent bile acids have variable degrees of hydrophobic-
ity and hydrophilicity, which are determined by their
biochemical and physicochemical properties (Sarbur
et al., 2001).
Bile acids synthesized within hepatocytes, are
termed primary bile acids, like the dihydroxylated
chenodeoxycholic acid (CDCA) and the more hy-
drophilic trihydroxylated cholic acid (CA). Within
the intestines, C-7 dehydroxylation of the primary
bile acids by bacteria, produces secondary bile acids,
identified as deoxycholic acid (DCA; from CA) and
lithocholic acid (LCA; from CDCA). The 7-hydroxy
epimerization of CDCA, results in ursodeoxycholic
acid (UDCA), currently used for cholesterol gallstone
dissolution therapy and in the treatment of cholestatic
liver diseases.
Within hepatocytes, all bile acids, whether primary
or secondary, are conjugated at the terminal (C24)
carboxyl group with glycine or taurine (Falany et al.,
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1994), with the glycine conjugates predominating in
man. This amidation increases aqueous solubility at
acidic pH, increases resistance to precipitation by
calcium and renders bile acids impermeable to cell
membranes (Hofmann and Mysels, 1988; Hofmann
and Hagey, 1998). Bile acid conjugates exist pre-
dominantly in their anionic form at physiological
pH (Hofmann, 1994). Therefore, they are called bile
salts. For a matter of simplicity we will name both
forms as bile acids.
The importance of bile acids as transcriptional
regulators of cholesterol homeostasis has becoming
increasingly evident. The amount of bile acid syn-
thesized by the liver, is closely regulated to prevent
overaccumulation of bile acids on one hand, and
cholesterol on the other. When bile acids accumulate
beyond physiologic levels, a negative feedback mech-
anism comes into play, and synthesis is decreased
(Russell and Setchell, 1992). Conversely, bile acid
synthesis is increased when the substrate, cholesterol,
accumulates. Both of these regulatory responses, are
transcriptional in nature and are mediated by mem-
bers of the nuclear hormone receptor family, acting
on two genes that encode hydroxylase enzymes in the
biosynthetic pathways (Chawla et al., 2001).
1.3. Bile acid transport
Bile acids undergo an extensive process of en-
terohepatic circulation (Müller and Jansen, 1997;
Meier and Steger, 2002). The polarized expression
of distinct transport systems at the basolateral (si-
nusoidal) and apical (canalicular) surface domains
of hepatocytes, allows an efficient vectorial hepato-
cellular secretion of bile acids from blood into bile.
Basolateral carrier proteins, the Na+-taurocholate co-
transport proteins and the Na+-independent organic
anion-transporting polypeptides, mediate hepatocel-
lular uptake of bile acids (Fig. 2). Intracellular cy-
tosolic bile acid-binding proteins and, although to a
lesser extent, vesicle-associated transport processes,
are responsible for the rapid diffusion across hepato-
cytes for canalicular secretion. Bile acids, are rapidly
pumped into the biliary canaliculus by the bile salt
export pump, which belongs to the ATP-binding cas-
sette transport superfamily. As bile flows through the
bile ducts, it is modified by addition of a watery,
bicarbonate-rich secretion from ductal epithelial cells.
Non-ionic diffusion and the apical sodium-dependent
bile salt transporter, reabsorb a minor portion of pro-
tonated bile acids and monomeric bile salts in bile
ductules. The multidrug-resistance-associated pro-
teins, then mediate basolateral export of bile acids
from the cholangiocytes (bile duct epithelial cells).
Bile acids are carried through bile ducts to the gall-
bladder, where they are stored for future use. Tran-
scriptional and post-transcriptional regulation of the
transporters involved in the enterohepatic circulation,
is closely related to the regulation of lipid homeosta-
sis (Fig. 2). Additionally, decreased or even absent
expression of hepatocellular transport systems, is an
important cause for various cholestatic liver diseases
(Trauner et al., 1998).
1.4. Potential toxicity of bile acids and cholestatic
liver diseases
The impairment of bile formation may be due to
drugs or infectious, autoimmune, metabolic, or ge-
netic disorders. Impairment of bile secretion, may re-
sult either from a functional defect in bile formation at
the level of the hepatocyte (intrahepatic cholestasis),
or from an impairment in bile secretion and flow at
the level of the biliary tree (extrahepatic cholestasis).
Even when the primary insult is to the bile ducts, hep-
atocellular injury is an invariable feature of cholesta-
sis, associated with the accumulation of bile acids in
the liver tissue and blood (Greim et al., 1973; Fischer
et al., 1996). The elevated hydrophobic bile acid con-
centrations will promote liver injury, that ultimately
lead to cirrhosis and liver failure, requiring transplan-
tation at a substantial society cost. In severe stages of
cholestatic diseases, liver transplantation is the only
solution. The recovery of bile excretion is a key early
event that determines the survival after transplanta-
tion. Impairment of bile flow upon transplantation will
promote further liver injury.
The pivotal role of bile acid-mediated hepatotoxic-
ity in the pathogenesis of the disease has been inten-
sively investigated in the last years, being supported by
a variety of data from clinical and experimental obser-
vations. Although secondary bile acids are extremely
toxic, their serum concentrations actually decrease in
chronic cholestasis, in contrast to the concentrations of
the primary ones, which increase. In healthy individu-
als, the portal vein serum total bile acid concentration
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Fig. 2. (A) Hepatocyte bile acid transporters and pathways involved in bile acid metabolism. (B) Cellular dysfunction induced by bile
acids: the prominent role of mitochondria. BSEP: bile salt export pump; CYP7: cholesterol 7alpha-hydroxylase; FXR: farnesoid X
receptor; MDR3: multidrug resistance protein; LXR: liver X receptor; MTP: mitochondrial permeability transition; NTCP: Na+-taurocholate
transporter; OATP: organic anion-transporting protein; PC: phospholipids; PPAR: peroxisome proliferator-activated receptor alpha; SREBP:
sterol regulatory element binding proteins.
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is approximately 20M; in cholestasis, concentra-
tions can reach 300M (Ostrow, 1993). Specifically,
the concentration of CDCA is significantly increased
(Fischer et al., 1996). Hydrophobic bile acids may
solubilize membrane-bound lipids, leading to dam-
age to cell membranes. However, at physiologically
relevant concentrations, a simple detergent-like ac-
tion disruption of membrane is probably not relevant
(Billington et al., 1980; Fischer et al., 1996).
Taking into consideration the multifaceted role of
mitochondria in cell homeostasis, it is natural to hy-
pothesize their role as a primary intracellular target,
important in the initiation of cell dysfunction dur-
ing cholestasis. Although numerous studies have been
made in the last years, in order to clarify mechanisms
of bile acid hepatotoxicity, one question remains un-
clear: is mitochondrial damage central and initiator
of the dysfunction or it has a secondary role in the
cholestatic process, being more a consequence than a
trigger? The following overview provides an impor-
tant insight into the role of mitochondria as a primary
intracellular target in the initiation of cell dysfunction
during cholestasis.
2. Mechanisms of bile acid
cytotoxicity—mitochondria as a target for bile
acid toxicity
2.1. Alteration of mitochondrial function by bile
acids in isolated mitochondria
Primary mitochondrial toxicity induced by bile
acids has been investigated in order to address its clin-
ical relevance for patients with cholestasis. Studies
with isolated rat liver mitochondria have been con-
ducted, providing a reliable basis to predict biochem-
ical and cellular mechanisms that mediate toxicity of
bile acids.
Increasing concentrations of the bile acids LCA,
DCA, UDCA, CDCA, glycochenodeoxycholic
(GCDC) or taurochenodeoxycholic (TCDC), were
shown to decrease mitochondrial membrane potential
(Ψ ) developed upon succinate energization (Rolo
et al., 2000). These compounds also decreased state 3
respiration and enhanced state 4 (Rolo et al., 2000).
The decrease in state 3 respiration is probably re-
lated with an inhibitory action of these compounds
on the phosphorylation system, albeit by a mecha-
nism that has yet to be defined. These observations
are in agreement with previous reports (Spivey et al.,
1993; Krähenbühl et al., 1994a) which indicates that
GCDC, DCA, LCA inhibited state 3 mitochondrial
respiration in a dose dependent manner. The described
concentration-dependent stimulation of state 4 by
LCA, DCA, CDCA, TCDC and GCDC, is associated
with an enhanced permeability of mitochondria to
protons (Rolo et al., 2000). The observed uncoupling
may be a consequence of several interactions of these
compounds with mitochondrial structure. TCDC,
GCDC, DCA, LCA, and CDCA, induced permeability
of the membrane to protons, either by a protonophoric
action or by disruption of membrane order.
The majority of compounds possessing protono-
phoric activity are lipophilic weak acids that have
dissociable protons and permeable bilayers either
as protonated acids, with pKa values in the range
of 5–7, or as the conjugate base. By cycling across
the membrane they can catalyze the net electrical
uniport of protons and increase the proton con-
ductance of the membrane. In so doing the proton
circuit is short-circuited, allowing the process of pro-
tonmotive force generation to be uncoupled from
ATP synthesis. Although unconjugated bile acids
are weak acids, they do not present the structural
requirements for uncoupling activity as classical un-
couplers such as FCCP, including the presence of
an acid-dissociable group, bulky lipophilic groups,
and a strong electron-withdrawing moiety. The phe-
nomenology of bile acid-induced uncoupling, could
resemble that of fatty acids (which is mediated by in-
tegral proteins of the inner mitochondrial membrane),
since they are sufficiently hydrophobic to penetrate
the lipid membrane. Further studies have shown that
CDCA renders mitochondrial membranes more per-
meable for concentrations as low as 50M, as shown
by the increased membrane fluidity probed by DPH
(Rolo et al., 2003a). This appears as the specific mech-
anism by which bile acids stimulate state 4 respiration.
It is well established that hydrophobicity, as demon-
strated by its close correlation with the partition coeffi-
cient of compounds, is often associated with biological
action (Hansch and Dunn, 1972). Bile acids, in partic-
ular the hydrophobic dihydroxy, such as CDCA, and
monohydroxy species, are surface-active substances
and can damage biological membranes (Scholmerich
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et al., 1984). Some reports, regarding in vitro studies,
have been shown direct effects of bile acids on mem-
brane fluidity (Isaacson and Van Thiel, 1988; Schroder
et al., 1996), associated with increased proton per-
meability of the membranes (Zhao and Hirst, 1990;
Schroder et al., 1996). On the reported studies (Zhao
and Hirst, 1990; Schroder et al., 1996), an evalua-
tion of dose-dependence showed that increased mem-
brane fluidity and proton permeability were observed
at concentrations as low as 100M. Moreover, it was
described that the alterations on membrane fluidity af-
fected specifically the inner membrane.
Induction of the mitochondrial permeability transi-
tion (MPT) is known to play a key role in cell death.
In isolated liver mitochondria preloaded with calcium,
LCA, DCA, CDCA, TCDC, GCDC and UDCA,
elicited a concentration-dependent induction of MPT
(Rolo et al., 2000), as already described for GCDC and
DCA (Botla et al., 1995; Gores et al., 1998). Pretreat-
ment with cyclosporin A (CyA), a specific and potent
inhibitor of the MPT (Broekemeier et al., 1989),
completely protected against the calcium-dependent
swelling. Therefore, MPT induction is involved in
bile acid cytotoxicity.
The plasma accumulation of bile acids has been
proposed as a causative factor for hepatic cardio-
myopathy (Joubert, 1978). Gazawi et al. sug-
gested that bile acid-induced modification of cardiac
-adrenoreceptor activity might represent a mecha-
nism whereby bile acids exert these effects on car-
diac performance (Gazawi et al., 2000). Carvedilol
({1-[carbazolyl-(4)-oxy]-3-[2-methoxyphenoxyethyl)
amino]-propanol-(2)}) is a lipophilic, vasodilating
-adrenoreceptor blocking agent, with known cardio-
protective properties. Among the various metabolites
of carvedilol, BM-910228 ({1-[3-hydroxycarbazolyl-
(4)-oxy]-3-[2-methoxyphenoxyethyl)amino]-propanol-
(2)}) is one of the most important. Although there are
still considerable uncertainties about the mechanisms
underlying the multiple cardioprotective effects of
carvedilol, its action could be related with protection
of mitochondrial function. Indeed, it has recently
been shown that carvedilol inhibits MPT induction
by an antioxidant mechanism (Oliveira et al., 2004).
Studies have been performed to address if carvedilol
potentially prevents mitochondrial dysfunction in-
duced by bile acids. In the presence of calcium and
phosphate, CDCA induced the permeability transition
in freshly isolated rat liver mitochondria, character-
ized by membrane depolarization, osmotic swelling,
release of matrix calcium and cytochrome c, that was
prevented by carvedilol (Rolo et al., 2001a,b, 2003b).
All these events were blocked by CyA, the calcium
uniporter ruthenium red (RR) and carvedilol. Under
the same conditions, the hydroxylated metabolite of
carvedilol, BM-910228 did not provide any protec-
tive effect. Since BM-910228, shown to have higher
antioxidant activity than carvedilol (Yue et al., 1994),
did not afford protection these results are consistent
with a protection by carvedilol that occurs via the in-
hibition of the MPT, not related with the antioxidant
properties (Rolo et al., 2001b).
Additionally, MPT induction by CDCA has been
shown to be associated with changes in mitochon-
drial membrane fluidity (Rolo et al., 2003a), inhibited
by carvedilol but not by its hydroxylated analog,
BM-910228. So, prevention by carvedilol could be re-
lated with the physical stabilization of mitochondrial
membrane, as opposed to disturbance induced by
CDCA. This would explain the similar results ob-
tained with CyA and carvedilol. Indeed, membrane
fluidity studies, reflecting the dynamic properties of
mitochondrial membranes, have shown the strict cor-
relation between the inhibitory effect of carvedilol
and the changes in the polarization values due to pore
opening (Rolo et al., 2003a). A direct interaction with
the pore assembly could also be a hypothesis to ex-
plain the action of carvedilol in modulating the ability
of CDCA to induce MPT. This difference between
carvedilol and metabolite may reflect the different
properties of both carvedilol and BM-910228 in terms
of membrane insertion. Due to its great lipophilicity,
carvedilol has a great tendency for membrane inser-
tion (Cheng et al., 1996) and may disturb the correct
assemblage of the proposed pore proteic components.
Interestingly, Rodrigues et al. (Rodrigues et al.,
1999, 2000) have shown that hydrophilic bile acids,
such as UDCA and its taurine derivative (TUDC),
are inhibitors of apoptosis via stabilization of the
mitochondrial membrane, through pathways that
are independent of the MPT. In fact, these stud-
ies regarding induction of apoptosis through a
mitochondrial-dependent pathway have showed that
although there was no protection by CyA, UDCA or
TUDC were able to prevent cell death. The proposed
mechanism for protection by hydrophilic bile acids
C.M. Palmeira, A.P. Rolo / Toxicology 203 (2004) 1–15 7
correlates inhibition of mitochondrial depolarization
and outer membrane disruption, together with mod-
ulation of Bax translocation from cytosol to mito-
chondria. This similarity of cytoprotective actions of
both carvedilol and hydrophilic bile acids may reflect
modulation of membrane perturbation due to their
lipophilicity. In contrast, and in concordance with
other reports (Rolo et al., 2000, 2003a), CyA blocked
MPT and also prevented mitochondrial swelling and
reduced the efflux of cytochrome c induced by DCA,
a hydrophobic bile acid (Rodrigues et al., 1999). This
suggests that, in contrast to hydrophilic bile acids,
cytotoxicity of hydrophobic bile acids involve mito-
chondrial disruption and cytochrome c release pri-
marily through MPT induction. A study with isolated
rat liver mitochondria by Solá et al. (Solá et al., 2002)
also described a CyA-sensitive release of cytochrome
c induced by hydrophobic bile acids at concentrations
lower than the ones necessary to induce structural
changes. This supports the hypothesis that mitochon-
drial toxicity induced by hydrophobic bile acids does
not result from generalized damage to the organelle
but is the result of specific events.
The central role of mitochondria in the progres-
sion of cholestatic injury, upon the initial phase of
accumulation of bile acids, was also supported by the
differential results upon chemically-induced acute or
chronic cholestasis. -naphthylisothiocyanate (ANIT)
has been employed as a mean to investigate the devel-
opmental aspects of the cholestatic type of hepatotoxic
response (Goldfarb et al., 1962; Plaa and Priestley,
1976; Lock et al., 1982). ANIT induces cholestasis
in a reproducible and dose-dependent manner fol-
lowing acute administration, bile duct hyperplasia
and biliary cirrhosis following chronic administration
(Plaa and Priestley, 1976). The cholestasis induced
by ANIT is attributed to an increased permeability
of the tight junctions between hepatocytes and bile
duct epithelial cells, and the subsequent diffusion
of osmotically active solutes from the bile into the
plasma. Liver mitochondrial bioenergetics was eval-
uated in -naphthylisothiocyanate (ANIT)-treated
Wistar rats (Rolo et al., 2002a), an experimental
model of cholestasis. In rats injected with ANIT,
liver injury with cholestasis developed within 48 h, as
indicated by both serum enzyme activities and total
bilirubin concentration. Liver mitochondria isolated
from ANIT-treated rats had a higher state 3 respira-
tion, respiratory control ratio, ADP/O, and endoge-
nous ATP/ADP ratio, when compared to controls. No
change in state 4 respiration was observed. Associ-
ated with these parameters, cholestatic mitochondria
exhibited an increased resistance to disruption of mi-
tochondrial calcium homeostasis, due to MPT induc-
tion. A more efficient mitochondrial function in acute
cholestasis, suggested an adaptive response by the
hepatocyte to limit liver damage, explaining the slow
progression of human cholestatic liver disease. These
observations are corroborated by a study reported by
Lieser et al., in which evaluation of a specific parame-
ter in mitochondria from bile duct ligated rat, revealed
less susceptibility to bile acid-induced MPT (Lieser
et al., 1998). Besides modulation of mitochondrial
function, liver adapts to cholestasis by attempting to
reduce intracellular bile acid concentrations, via regu-
lation of bile acid transporters expression. Decreased
expression of the basolateral uptake transporter and
maintenance or increased expression of efflux trans-
porters has been documented (Gartung et al., 1996;
Lee et al., 2000). Another facet is enhancement of
renal excretion of bile acids upon sulfation.
However, after chronic cholestasis, these adapta-
tions do not prevent a persistent, probably irreversible
toxic action of bile acids, and disruption of mitochond-
rial calcium homeostasis is observed (Rolo et al.,
2002b). Interestingly, ability of bile acids to induce
calcium release from intracellular stores, does not
involve solely the mitochondria, as observed in our
work, but also the endoplasmic reticulum (Combettes
et al., 1988; Rolo et al., 2002b). The rise in intra-
cellular calcium may lead to an increase in calcium-
dependent proteolysis and, ultimately, cell death.
2.2. Alterations in cell function upon exposure to
bile acids
Two distinct mechanisms of cell death are trig-
gered by hydrophobic bile acids: necrosis at higher
concentrations (≥250M) and apoptosis at lower
concentrations (≤100M). To further elucidate mito-
chondrial role in necrotic cell death induced by toxic
bile acids, mitochondrial function, namely the role of
the MPT, was evaluated in primary cultures of hepa-
tocytes upon exposure to CDCA, a major contributor
to cholestatic liver diseases (Rolo et al., 2003b). In-
duction of the MPT, inhibition of ATP synthesis and
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consequent metabolic starvation of the cell was the
sequence of events triggered by CDCA at 250M,
after short time incubation (4 h) (Rolo et al., 2003b).
Accordingly, Spivey et al. have previously shown
that glycochenodeoxycholate, the glycine conjugate
of CDCA, induces lethal hepatocellular injury depen-
dent on ATP depletion (Spivey et al., 1993). Fructose,
which is an alternate glycolytic source of cellular
ATP, protects against ATP depletion and cell killing
induced by CDCA (Rolo et al., 2003b). Because mito-
chondria are the primary source of ATP in liver cells,
these studies indicate that impairment of mitochon-
drial oxidative phosphorylation is an early and critical
event in the mechanism of bile acid cytotoxicity.
The increase in reactive oxygen species (ROS) by
bile acids has been largely documented (Sokol et al.,
1991, 1995, 1998; Patel and Gores, 1997; Rodrigues
et al., 1998; Shivaram et al., 1998). MPT induction and
subsequent release of cytochrome c may explain the
observations that bile acid cytotoxicity is associated
with generation of ROS. Indeed, loss of cytochrome
c from the mitochondria, results in impaired electron
flow on the respiratory chain, promoting electron leak
at the level of ubiquinone-complex III and increased
ROS generation. Additionally, the observed decrease
in state 3 respiration may be the result of a direct
effect on enzyme complexes or due to cytochrome
c release induced by bile acids. In this case, oxida-
tive stress does not result from a primary effect of
bile acids, but is a secondary phenomenon. Although
not involved in the pathogenesis of cholestatic liver
injury, high plasma concentrations of lipid peroxides
are observed in humans with cholestasis (Lemonnier
et al., 1987). A possible adaptation of liver cells to
prevent further damage is the up-regulation of glu-
tathione synthesis, as observed in bile duct-ligated rats
(Baron and Muriel, 1999). Although administration of
antioxidants in this experimental model of cholestasis
preserves the normal glutathione/glutathione disulfide
(GSH/GSSG) ratio and prevents lipid peroxidation,
liver injury, as assessed by serum enzyme activities
and tissue histology, was not affected by the treatment
(Ballatori and Truong, 1990). This further supports
that oxidative stress is a consequence and not a cause
of bile acid toxicity.
Hepatocyte apoptosis is a common pathologic fea-
ture of cholestatic liver diseases. Interestingly and op-
posingly to necrosis (Rolo et al., 2002c), at the level
of apoptosis induction, cytotoxicity of bile acids does
not always correlate with their hydrophobicity. In-
deed, apoptosis induction is dependent on the bile
acid, its concentration, or its conjugation state. For
example, the glycine conjugated of CDCA (GCDC)
was shown to induce hepatocyte apoptosis, whereas
the taurine conjugate (TCDC) did not (Patel et al.,
1994). Rust et al. described that TCDC, but not GCDC,
a hydrophobic bile acid, at 50M activated a phos-
phatidylinositol 3-kinase-dependent survival pathway
in McNtcp.24 rat hepatoma cell line (Rust et al., 2000).
A downstream event in this signaling pathway is phos-
phorylation of Bad, a pro-apoptotic member of the
Bcl-2 family (Datta et al., 2002). Moreover, inhibition
of this pathway, converted TCDC to a potent apop-
totic inducer (Rust et al., 2000). Early studies by Jones
et al., pointed that protein kinase C-dependent signal-
ing pathway, plays a critical role in GCDC-induced
hepatocyte apoptosis, triggering activation of the pro-
tease cathepsin B (Jones et al., 1997).
Thus, depending on the conjugation status of the
bile acid, different signaling pathways are recruited
to preserve cell viability. Interestingly, treatment of
hepatocytes with 50M DCA, CDCA, and UDCA
caused a similar activation of the mitogen-activated
protein kinase (MAPK) pathway (Qiao et al., 2002).
Partial activation of this pathway provided a significant
cytoprotective downstream signal (Qiao et al., 2002),
modulating bile acid toxicity.
Studies have been performed to evaluate if mi-
tochondrial dysfunction is a primary pathway for
CDCA-induced apoptosis. Upon 24 h, HepG2 cells
exposed to 50M CDCA underwent a significant
inhibition of cell proliferation, characterized by an S
phase block (Rolo et al., 2004). Inhibition of cell pro-
liferation by conjugated and unconjugated bile acids,
was also observed in rat hepatocytes in primary cul-
ture (Martinez-Diez et al., 2000). At 48 h, apoptosis
induction by CDCA was observed (Rolo et al., 2004).
The observed MPT induction, consequent cytochrome
c release and caspase-9 activity, in CDCA-induced
apoptosis, are hallmarks of the mitochondrial pathway
in apoptotic cell death (Rolo et al., 2004). Another ev-
idence for the role of this pathway in bile acid-induced
apoptosis was recently pointed by Graf et al. (Graf
et al., 2002). In this study, GCDC induced-cell death in
hepatocytes was prevented by betaine, through modu-
lation of cytochrome c release and caspase-9 activity.
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Inhibition of caspase-9 strongly inhibited caspase-8
activity (Graf et al., 2002), supporting that caspase-8
activity is a consequence of the early activation of the
apoptotic programme at the mitochondrial level.
MPT induction in apoptosis induced by other bile
acids has been demonstrated. Yerushalmi et al. have
demonstrated that antioxidants prevented GCDC-
induced apoptosis in rat hepatocytes, through a mech-
anism involving the MPT (Yerushalmi et al., 2001).
Interestingly, Gumpricht et al. described that the glu-
tathione status of the hepatocyte, altered the cell’s
response to GCDC-induced necrosis but not apoptosis
(Gumpricht et al., 2000). Rodrigues et al. have doc-
umented that apoptosis triggered by DCA, involved
decreased mitochondrial transmembrane potential
and alterations in Bax subcellular distribution, with
increased mitochondrial-associated Bax protein lev-
els (Rodrigues et al., 1999). It looks like that MPT
induction by bile acids is the initial event, and the
initial cytochrome c release stimulates Bax translo-
cation to the mitochondria, accomplishing further
cytochrome c release (Rodrigues et al., 1999). In vivo
studies show that after bile duct-ligation, Bax, which
is normally distributed thoughout the cytoplasmic,
mitochondrial, and perinuclear space, translocates to
the mitochondria (Oh et al., 2003). The same study
described an increase in Bax expression, 3 days after
bile duct-ligation and a decrease over time there after.
Cytochrome c release was also evident (Oh et al.,
2003).
Toxic bile acid-induced hepatocyte apoptosis in-
volves both extrinsic (death receptor-mediated apop-
tosis) and intrinsic (direct targeting to mitochondria)
apoptotic pathways. The intrinsic apoptotic pathway
involves direct effects of bile acids on mitochondria
with subsequent release of apoptogenic factors as
reviewed in this paper. Several studies have demon-
strated the importance of death receptor-mediated
apoptosis in bile acid cytotoxicity (Miyoshi et al.,
1999; Sodeman et al., 2000; Higuchi et al., 2001,
2003). In this pathway, binding to death receptors (Fas
pathway) activates procaspase-8, which cleaves and
activates procaspase-3, initiating the caspase cascade
(Fig. 2). However, the direct effect of caspase-8 on
effector caspases is relatively small and is amplified
by a mitochondrial pathway, in which cytochrome c
release is induced by translocation to mitochondria
of the cleaved or truncated form of Bid (Fig. 2). Both
apoptotic pathways converge at the level of the exe-
cution phase, with activation of executioner caspases
and cleavage of target substrates.
3. UDCA therapy: evidence for hepatoprotective
effects involving other complementary mechanisms
rather than modulation of mitochondrial function
In recent years, the therapeutic benefit of UDCA has
been extensively investigated. Although several stud-
ies found improvement in serum markers of liver in-
jury in some patients (van Hoogstraten et al., 1999),
other studies found no benefit, especially success rates
of liver transplantation and death (Neuberger, 2000).
In patients with significantly higher cholestasis in-
dices, the bile acid therapy is more incomplete. There-
fore, multiple therapies have been tried (Angulo and
Lindor, 1998).
Modulation of mitochondrial membrane perturba-
tion by UDCA and inhibition of MPT induction by
other bile acids (Gores et al., 1998; Rodrigues et al.,
1998, 1999) have been the mechanisms proposed for
UDCA’s hepatoprotective properties. So, UDCA has
been described as the perfect therapy for cholestatic
liver diseases and an anti-apoptotic agent in both hepa-
tocytes and extrahepatic cells (Rodrigues et al., 1998).
However other studies have shown potentiation by
UDCA of mitochondrial and cell dysfunction induced
by other bile acids (Kessel et al., 2000; Rolo et al.,
2000, 2003b, 2004; Oyama et al., 2002).
Indeed, UDCA has been shown as a potent in-
ducer of the calcium-dependent MPT, potentiated bile
acid-induced necrosis and converted CDCA-induced
apoptosis in major necrosis (Rolo et al., 2000, 2002c,
2003b, 2004). Both events were mediated by potenti-
ation of MPT induction, as indicated by the increased
mitochondrial depolarization prevented by CyA. In-
terestingly, UDCA did not increase membrane perme-
ability to protons, supporting that at concentrations
as high as 500M UDCA has no deleterious effect
on membranes. No direct effect of UDCA on mem-
brane fluidity or protein order was described by Solá
et al. (Solá et al., 2002). This may be the result of
the orientation of the steroid hydroxyl groups. Com-
paring with other bile acids, UDCA, which is the
-epimer of CDCA, is more hydrophilic. We may
recall that, CDCA at concentrations as low as 50M,
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induced increased membrane fluidity (Rolo et al.,
2003a). Although being an inducer of the MPT in
isolated mitochondria, UDCA (50M) did not elicit
cytochrome c release in HepG2 cells in culture (Rolo
et al., 2004). However, isolated hepatocytes exposed
to 250M UDCA underwent a progressive release of
lactate dehydrogenase (Rolo et al., 2002c). This effect
in cell viability was consequence of UDCA-induced
mitochondrial dysfunction through MPT induction.
Indeed, an early study by Krähenbühl et al., demon-
strated that although UDCA did not impair mito-
chondrial function up to concentrations of 100M, at
300M, state 3 respiration and respiratory control ra-
tio decreased (Krähenbühl et al., 1994b). Since at this
concentration we observed calcium-dependent-MPT
induction by UDCA, this could be the mechanism
by which UDCA impairs mitochondrial respiration.
At this concentration, UDCA also potentiated impair-
ment of mitochondrial respiration induced by CDCA
and LCA (Krähenbühl et al., 1994b), as well as MPT
induction.
In consequence of UDCA effect on mitochondrial
function, it potentiated mitochondrial dysfunction and
cell death induced by hydrophobic bile acids. In con-
trast, previous studies by Rodrigues et al., besides
preventing mitochondrial depolarization induced by
DCA, UDCA at 500M also prevents DCA-induced
Bax translocation to mitochondria, cytochrome c re-
lease and apoptosis induction (Rodrigues et al., 1998,
1999). Additionally, it has also been shown that in
vivo DCA feeding is associated with a 4.5-fold in-
crease in mitochondrial-associated Bax protein levels,
while combination feeding with UDCA significantly
inhibited these changes (Rodrigues et al., 1998).
A probable explanation for these discrepant results
regarding MPT induction by UDCA resides in the
preloading of mitochondria with calcium. Exposure
of calcium-loaded mitochondria (calcium at a con-
centration which per se does not induce the MPT)
to UDCA results in increased mitochondrial swelling,
prevented by CyA (Rolo et al., 2000). In contrast,
Rodrigues et al. (Rodrigues et al., 1998, 1999), and
also Gores et al. (Gores et al., 1998), evaluate UDCA
effects on MPT in a medium in which calcium is
absent. So, UDCA alone appears not to cause mito-
chondrial membrane damage but it lowers the thresh-
old at which calcium induces the MPT. This role of
calcium in modulating UDCA effects on the cell is fur-
ther supported by UDCA-induced stimulation of cal-
cium release from intracellular stores and subsequent
apoptosis activation (Strupp et al., 2000). The activa-
tion of a pro-apoptotic cascade by UDCA, which is
then blocked by the simultaneous activation of a sur-
vival pathway, has also been observed by Qiao et al.
(Qiao et al., 2001). However, the role of calcium is
not clear, because the apoptotic response of cells ex-
posed to UDCA, was not blocked in a calcium free
culture media neither in the presence of an intracellu-
lar calcium chelator (Qiao et al., 2001). A possible in-
volvement of sphingomyelinase activation by UDCA
(Duan and Nilsson, 1997; Cheng et al., 1999), and
subsequent generation of ceramide, may be involved
in UDCA-induced cell death (Qiao et al., 2001). Ce-
ramide plays a role in the regulation of cell life and
death (Cremesti et al., 2001) and increases mitochon-
drial membrane permeability.
Other authors have described potentiation of cell
dysfunction induced by UDCA. UDCA induces
apoptosis in hepatocellular carcinoma cells, medi-
ated by increased levels of Bax in mitochondria and
cytochrome c in the cytosol (Oyama et al., 2002).
Preincubation of murine leukemia and hepatoma cells
with UDCA, potentiated the effects of photodynamic
therapy (Kessel et al., 2000). Such action, involved
effects at the level of mitochondrial depolarization,
release of cytochrome c into the cytosol, and ac-
tivation of caspase-3. Glyco- and tauro-conjugates
of UDCA displayed the same action (Kessel et al.,
2000). In contrast, TUDC proved to be effective in
reducing both GCDC-induced apoptosis and cytol-
ysis (Benz et al., 1998). The condition that UDCA
exerts such an effect, if present before but not upon
irradiation (Kessel et al., 2000), supports the sugges-
tion that UDCA per se does not cause mitochondrial
membrane damage but lowers the threshold for the
action of other compounds.
A new perspective on the hepatoprotective effect
of UDCA that has been pointed out, is related with
oxidative injury and antioxidant systems in cultured
rat hepatocytes. Mitsuyoshi et al., observed that pre-
treatment with UDCA, significantly prevented the
dose-dependent decrease of the viability of the hep-
atocytes after hydrogen peroxide or cadmium ad-
ministration (Mitsuyoshi et al., 1999). Such event
was correlated with increased amounts of glutathione
(GSH) and protein thiols. Additionally, it has also
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been reported, significantly higher mRNA levels of
-glutamylcysteine synthetase (a rate-limiting en-
zyme in glutathione synthesis) and metallothionein in
UDCA-treated hepatocytes (Mitsuyoshi et al., 1999).
Activation of metallothionein promoter by UDCA was
also shown in HepG2 cells (Bernstein et al., 2002)
Tanaka et al. reported that, in rats with DCA-induced
liver injury, UDCA prevents the decrease in hepatic
cytochrome P450 enzymes (Tanaka et al., 1999). It is
then suggested that UDCA, is useful for the treatment
of liver injury in terms of helping the normalization
of the hepatic drug-metabolizing system, which has
been shown to be influenced by cholestasis (George
et al., 1995; Chen and Farrel, 1996).
Our observations suggest that any therapeutic ef-
fect of UDCA must be secondary to an altered mem-
brane transport or non-parenchymal cell function. It
has been postulated, that one of the main therapeutic
mechanisms of UDCA in cholestatic liver diseases, re-
lates to displacement of the endogenous hepatotoxic
bile by expansion of the hydrophilic bile acid pool
(i.e., enrichment by UDCA). Exogenously adminis-
tered UDCA is absorbed and conjugated to taurine and
glycine in the liver. The conjugates of UDCA compete
with the toxic hydrophobic bile salts for uptake in the
enterohepatic circulation. So, UDCA’s beneficial ef-
fects are generally attributed to its ability to enrich the
hepatic bile acid pool, replacing or displacing more
hydrophobic bile acids from the hepatocyte. This pro-
tective function of UDCA may correlate with competi-
tive displacement of endogenous (i.e., toxic) bile acids
either at the level of ileal absorption or at the hep-
atocyte level (i.e., cell plasma membrane, intracellu-
lar organelles). Moreover, UDCA-stimulated calcium
entry across the hepatocellular plasma membrane or
liberation from cellular calcium stores, is associated
with increased vesicular exocytosis of toxic bile salts
(Beuers et al., 1993).
UDCA also improves biliary secretion of bile acids,
may improve bile flow, and it has immunomodulatory
properties that may reduce immune-mediated liver
damage. It results in choleresis, with increased ca-
pacity of bile duct cells to secrete hydrophobic bile
acids, and a reduction in serum levels of CDCA in
patients with primary biliary cirrhosis (Beuers et al.,
1998). Biliary secretion of phospholipids, which may
also be hepatoprotective, appears to be increased with
UDCA therapy.
4. Conclusions
The data reviewed here demonstrate the key role of
mitochondria in bile acid cytotoxicity (Fig. 2).
In isolated mitochondria, hydrophobic bile acids
induce alterations in membrane fluidity associated
with impairment of mitochondrial respiration and mi-
tochondrial depolarization. MPT induction and subse-
quent cytochrome c release are also primary events in
bile acid toxicity. Such events, unless prevented by ef-
ficient mitochondrial protective agents, will progress
to cell death. Upon exposure to low bile acid con-
centrations, release of apoptogenic factors, activation
of caspases and DNA fragmentation entails apoptotic
cell death. Additionally and besides direct targeting to
mitochondria, apoptotic cell death is also induced by
bile acids through receptor-dependent-mechanisms.
In acute cholestasis, which may correspond to an
initial phase of relatively low concentrations of bile
acids accumulated in the hepatocyte, an enhancement
of mitochondrial function is probably an adaptive
mechanism to limit cell injury. However, high concen-
trations of bile acids cause a bioenergetic catastrophe
culminating in the disruption of plasma mem-
brane integrity. Concomitantly, in chronic cholesta-
sis mitochondrial calcium homeostasis is severely
impaired.
Although currently used as a therapeutic agent in
cholestatic liver diseases, UDCA displays a toxic
character. MPT induction and consequent mitochon-
drial depolarization are hallmarks of UDCA mitotox-
icity. Such effects potentiate cell dysfunction induced
by hydrophobic bile acids. Since bile acids used in
therapy, do not display the ability to antagonize reac-
tions induced by toxic bile acids as the mechanism
by which they might afford cytoprotection against
cholestasis, other diverse, complementary array of
mechanisms are involved. Improvement of biliary
secretion of bile acids and bile flow, expansion of
the hydrophilic bile acid pool or immunomodulatory
action are hypotheses. Furthermore, after chronic ad-
ministration of ANIT, our results indicate that UDCA
has no role in preventing mitochondrial dysfunction
induced by toxic bile acids. A study by Hillstrom
et al., also demonstrates that UDCA treatment before
and during administration of cholestatic drugs, did
not ameliorate cholestatic indices in animal models
of cholestasis (Hillstrom et al., 1992).
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